TY  - JOUR
T1  - EArly refractive outcome after intravitreous bevacizumab for retinopathy of prematurity
AU  - Harder BC, von Baltz S, Schlichtenbrede FC, Jonas JB
Y1  - 2012/06/01
N1  - 10.1001/archophthalmol.2012.1
JO  - Archives of Ophthalmology
SP  - 800
EP  - 801
VL  - 130
IS  - 6
N2  - 
Retinopathy of prematurity (ROP) is a neovascular retinal disease that has usually been treated by peripheral argon laser coagulation. Retinal laser coagulation has disadvantages and adverse effects such as the need for general anesthesia, scarring of the peripheral retina and choroid, and presumably induction of myopization.1- 2 Based on the role of vascular endothelial growth factor in retinal neovascularization, recent studies have shown the therapeutic effect of intravitreous bevacizumab as a vascular endothelial growth factor inhibitor for the therapy of ROP.3- 4 Besides the short-term effects of this anti–vascular endothelial growth factor therapy in terms of a regression of retinal neovascularization, effects of the therapy on the development of myopia have not yet been examined. We therefore assessed the refractive error of children who had received intravitreous bevacizumab for therapy of ROP.

SN  - 0003-9950
M3  - doi: 10.1001/archophthalmol.2012.1
UR  - http://dx.doi.org/10.1001/archophthalmol.2012.1
ER  -